Fujian Cosunter Pharmaceutical (300436.SZ) received approval for the listing of its innovative antiviral drug Taizhongding in Macau.

Fujian Cosunter Pharmaceutical (300436.SZ) announced that its innovative drug holding subsidiary Fujian Guangsheng Zhonglin Biological Technology Co., Ltd.'s novel drug Atetewei tablets (project code: GST-HG171)/ritonavir combination packaging (brand name: Taizhongding) has obtained the approval for new drug marketing from the Macao Special Administrative Region Government Pharmaceutical supervision and management bureau and has obtained a registration certificate for the finished drug. The drug is indicated for the treatment of adult patients with mild to moderate novel coronavirus infection.